S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

AnaptysBio Stock Forecast, Price & News

+0.17 (+0.84%)
(As of 07/1/2022 08:44 PM ET)
Today's Range
50-Day Range
52-Week Range
191,000 shs
Average Volume
265,937 shs
Market Capitalization
$576.97 million
P/E Ratio
Dividend Yield
Price Target

AnaptysBio MarketRank™ Forecast

Analyst Rating
2.33 Rating Score
93.0% Upside
$39.50 Price Target
Short Interest
15.29% of Float Sold Short
Dividend Strength
News Sentiment
0.33mentions of AnaptysBio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$14.45 M Bought Last Quarter
Proj. Earnings Growth
From ($4.27) to ($4.26) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.78 out of 5 stars

Medical Sector

756th out of 1,412 stocks

Pharmaceutical Preparations Industry

373rd out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

AnaptysBio logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Stock News Headlines

The Safest Way To Start Trading Is Here!
One look at Wall Street right now and anyone can tell: it’s a mess! But new trades can get an edge with “Options Trading Made Easy” by trading champion Chuck Hughes, the best guide to options trading in the modern market. Start with a small investment today and see where you can go! Get your copy now!
AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $19.82
The Safest Way To Start Trading Is Here!
One look at Wall Street right now and anyone can tell: it’s a mess! But new trades can get an edge with “Options Trading Made Easy” by trading champion Chuck Hughes, the best guide to options trading in the modern market. Start with a small investment today and see where you can go! Get your copy now!
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-57.80 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$63.17 million
Book Value
$12.89 per share


Free Float
Market Cap
$576.97 million

AnaptysBio Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price objectives for AnaptysBio's shares. Their ANAB stock forecasts range from $33.00 to $46.00. On average, they expect AnaptysBio's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 93.0% from the stock's current price.
View analysts' price targets for AnaptysBio
or view top-rated stocks among Wall Street analysts.

How has AnaptysBio's stock performed in 2022?

AnaptysBio's stock was trading at $34.75 at the start of the year. Since then, ANAB stock has decreased by 41.1% and is now trading at $20.47.
View the best growth stocks for 2022 here

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for AnaptysBio

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.44. The biotechnology company earned $0.97 million during the quarter, compared to analysts' expectations of $8.08 million. AnaptysBio had a negative net margin of 143.46% and a negative trailing twelve-month return on equity of 20.44%.
View AnaptysBio's earnings history

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Daniel R. Faga, Interim Pres & CEO and Director (Age 42, Pay $3.91k)
  • Mr. Eric J. Loumeau, COO & Gen. Counsel (Age 59, Pay $639.88k) (LinkedIn Profile)
  • Mr. Hamza Suria M.B.A., M.Sc., Advisory (Age 46, Pay $836.53k)
  • Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer (Age 47, Pay $683.17k)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 67)
  • Ms. Beth Mueller, Sr. VP of HR
  • Dr. Martin Dahl Ph.D., Sr. VP of Discovery Biology

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $20.47.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $576.97 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57.80 million in net income (profit) each year or ($2.75) on an earnings per share basis.

How many employees does AnaptysBio have?

AnaptysBio employs 102 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for AnaptysBio is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.